Biohaven Ltd. (NYSE:BHVN) Receives $18.69 Average Target Price from Brokerages

Posted by on Sep 16th, 2026

Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seventeen brokerages that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, eight have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $18.6875.

A number of brokerages recently commented on BHVN. TD Cowen reaffirmed a “buy” rating on shares of Biohaven in a report on Wednesday, August 26th. Canaccord Genuity Group set a $21.00 target price on shares of Biohaven in a research note on Friday, August 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Biohaven in a report on Friday, August 28th. HC Wainwright restated a “neutral” rating and set a $10.00 target price on shares of Biohaven in a report on Thursday, September 10th. Finally, Needham & Company LLC set a $11.00 price target on shares of Biohaven in a research report on Monday, June 29th.

Read Our Latest Stock Report on BHVN

Institutional Trading of Biohaven

A number of institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC lifted its stake in shares of Biohaven by 1,145.9% during the first quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock worth $148,214,000 after buying an additional 16,127,247 shares during the period. BlackRock Inc. purchased a new stake in shares of Biohaven in the second quarter worth about $196,574,000. Jupiter Topco LLC purchased a new stake in Biohaven in the 2nd quarter worth approximately $127,852,000. Vanguard Group Inc. boosted its holdings in Biohaven by 52.9% during the fourth quarter. Vanguard Group Inc. now owns 4,395,946 shares of the company’s stock worth $49,630,000 after buying an additional 1,520,756 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Biohaven by 148.2% during the 4th quarter. BNP Paribas Financial Markets now owns 2,093,816 shares of the company’s stock valued at $23,639,000 after acquiring an additional 1,250,252 shares during the period. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Stock Down 2.7%

Shares of BHVN stock opened at $12.30 on Friday. The company has a quick ratio of 4.73, a current ratio of 4.73 and a debt-to-equity ratio of 21.23. The stock has a market cap of $1.86 billion, a P/E ratio of -2.65 and a beta of 1.28. Biohaven has a 52 week low of $7.48 and a 52 week high of $18.57. The company’s fifty day simple moving average is $14.60 and its two-hundred day simple moving average is $12.13.

Biohaven (NYSE:BHVN – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.15). Analysts predict that Biohaven will post -3.33 EPS for the current fiscal year.

About Biohaven

(Get Free Report)

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and immunological disorders. The company’s research programs use a range of approaches, including small-molecule medicines, biologics and other targeted therapies, with the goal of addressing diseases that have limited or inadequate treatment options.

Biohaven’s pipeline has included investigational treatments for conditions such as epilepsy, obsessive-compulsive disorder, neurodegenerative diseases, neuroinflammatory disorders and immune-mediated diseases.

Featured Stories

Analyst Recommendations for Biohaven (NYSE:BHVN)

Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.